# US 2026/0009033 A1 · Antisense polynucleotides to induce exon skipping and method of treating dystrophies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0009033 A1
- Document ID: US20260009033A1
- Status: Published application
- Kind: A1
- Application number: 19/333,879
- Filed: 2025-09-19
- Published: 2026-01-08
- Earliest claimed: 2012-09-06
- Assignees: The University of Chicago
- Applicants: The University of Chicago
- Inventors: Elizabeth McNally
- Web page: https://patentgrep.com/patent/US20260009033A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- C12N 15/1138: {against receptors or cell surface proteins}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 2310/11: Antisense
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/3233: Morpholino-type ring
- C12N 2310/351: Conjugate
- C12N 2310/3535: Nitrogen
- C12N 2320/30: Special therapeutic applications
- C12N 2320/33: Alteration of splicing
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Antisense polynucleotides and their use in pharmaceutical compositions to induce exon skipping in targeted exons of the gamma sarcoglycan gene are provided, along with methods of preventing or treating dystrophic diseases such as Limb-Girdle Muscular Dystrophy.

## Claims

### Claim 1

An isolated antisense polynucleotide wherein the polynucleotide specifically hybridizes to an exon target region of a gamma sarcoglycan RNA, wherein the exon is selected from the group consisting of exon 4 (SEQ ID NO: 1), exon 5 (SEQ ID NO: 2), exon 6 (SEQ ID NO: 3), exon 7 (SEQ ID NO: 4) and a combination thereof.

### Claim 2 (depends on 1)

The antisense polynucleotides of claim 1, wherein the polynucleotide cannot form an RNase H substrate.

### Claim 3 (depends on 1, 2)

The antisense polynucleotide of claim 1 or claim 2, comprising a modified polynucleotide backbone.

### Claim 4 (depends on 1, 2, 3)

The antisense polynucleotide of any one of claims 1-3, wherein the modified polynucleotide backbone comprises a modified moiety substituted for the sugar of at least one of the polynucleotides.

### Claim 5 (depends on 5)

The antisense polynucleotide of claim 5, wherein the modified moiety is a Morpholino.

### Claim 6 (depends on 3, 4, 5)

The antisense polynucleotide of any one of claims 3-5, wherein the modified polynucleotide backbone of at least one of the polynucleotides comprises at least one modified internucleotide linkage.

### Claim 7 (depends on 6)

The antisense polynucleotide of claim 6, wherein the modified internucleotide linkage comprises a modified phosphate.

### Claim 8 (depends on 7)

The antisense polynucleotide of claim 7, wherein the modified phosphate is selected from the group consisting of a methyl phosphonate, a methyl phosphorothioate, a phosphoromorpholidate, a phosphoropiperazidate and a phosphoroamidate.

### Claim 9 (depends on 3, 4, 5, 6, 7, 8)

The antisense polynucleotide of any one of claims 3-8, wherein the polynucleotide is a 2′-O-methyl-oligoribonucleotide.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The antisense polynucleotide of any one of claims 1-9, wherein the polynucleotide is chemically linked to one or more conjugates that enhance the activity, cellular distribution, or cellular uptake of the antisense polynucleotide.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A pharmaceutical composition, comprising the antisense polynucleotide of any one of claims 1-10 and a physiologically compatible phosphate buffer.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A kit comprising the antisense polynucleotide of any one of claims 1-10, optionally in a container, and a package insert, package label. instructions or other labeling.
